MDNA begins global roll-out with appointment of distribution partner in South Korea

MDNA Life Sciences announces that it has entered into an exclusive license agreement with its first international commercial partner.

WEST PALM BEACH, Fla., Feb. 16, 2017 /PRNewswire/ – MDNA Life Sciences Inc. (MDNA), a molecular diagnostics company revolutionizing the development of liquid biopsy tests based on the mitochondrial genome, announces that it has entered into an exclusive license agreement with its first international commercial partner, BL&H who will distribute MDNA’s proprietary liquid biopsy test for prostate cancer, the Prostate Mitomic Test (PMT™), in South Korea. This is the first overseas appointment for MDNA as the Company implements its international roll out strategy to license partners across the globe to market its range of Mitomic liquid biopsy tests for the accurate identification and monitoring of a range of cancers and other diseases.

PMT™ has the potential to make a significant impact in the market in South Korea by helping clinicians to identify cases where biopsy can be safely delayed or even avoided altogether by differentiating between those patients who are likely to have high-grade cancer from those who are not. PMT™ will be offered alongside BL&H’s complement of therapeutic tests.

“Under the license agreement, BL&H will validate PMT™ in South Korea and market it as a more effective screening test for prostate cancer than the currently used PSA test which is widely acknowledged to be inaccurate. BL&H has extensive regulatory experience and has strong relationships with key hospital centers in South Korea. We look forward to building on this relationship by licensing additional Mitomic diagnostic tests to BL&H as they become available,” stated Chris Mitton, president and CEO of MDNA.

Mr. DC Roh, president of BL&H said: “We are very excited to bring the Prostate Mitomic Test to the South Korean market. PMT™ represents a unique commercial opportunity for our company because of its accurate detection of prostate cancer. The South Korean market has nothing like PMT™ and we expect it to be an important product for our company for many years to come.”

About BL&H

BL&H meets the demands of healthcare professionals by providing access to advanced and innovative products that offer patients a better quality of life. Their combined business, medical, regulatory and scientific expertise facilitates their approach to maximizing distribution of these high-quality, cutting-edge diagnostic tests. For more information visit

About MDNA Life Sciences Inc.

MDNA Life Sciences, Inc. is leading the development of molecular diagnostic tests using its proprietary Mitomic Technology™ platform that exploits the unique biological characteristics of mitochondrial DNA, a highly attractive and effective system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting. This innovative platform has led to the discovery of numerous novel and proprietary biomarkers for a multitude of cancers and other diseases. The Company is applying its expertise in mitochondrial genomics to develop an extensive and proprietary portfolio of blood-based molecular tests for conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. PMT™ is MDNA’s second Mitomic test for prostate cancer with market-leading assay performance, the first being a post-biopsy tissue-based test. For more information visit

For further information, please contact:

Christopher Mitton
[email protected]